Open Access

REVIEW

ELHAM SHAKIBA¹, SETI BOROOMAND², SIMA KHERADMAND KIA³, MEHDI HEDAYATI^4,*
Oncology Research, Vol.32, No.6, pp. 1011-1019, 2024, DOI:10.32604/or.2024.049235 - 23 May 2024
Abstract This review aimed to describe the inculpation of microRNAs (miRNAs) in thyroid cancer (TC) and its subtypes, mainly medullary thyroid carcinoma (MTC), and to outline web-based tools and databases for bioinformatics analysis of miRNAs in TC. Additionally, the capacity of miRNAs to serve as therapeutic targets and biomarkers in TC management will be discussed. This review is based on a literature search of relevant articles on the role of miRNAs in TC and its subtypes, mainly MTC. Additionally, web-based tools and databases for bioinformatics analysis of miRNAs in TC were identified and described. MiRNAs can… More >

Graphic Abstract

View

1303

Download

316

Open Access

ARTICLE

HYUNHO KIM¹, UIJU CHO², SOOK HEE HONG³, HYUNG SOON PARK¹, IN-HO KIM³, HO JUNG AN¹, BYOUNG YONG SHIM¹, JIN HYOUNG KANG^3,*
Oncology Research, Vol.32, No.6, pp. 1021-1030, 2024, DOI:10.32604/or.2024.048919 - 23 May 2024
Abstract Background: Apolipoprotein B mRNA editing catalytic polypeptide (APOBEC), an endogenous mutator, induces DNA damage and activates the ataxia telangiectasia and Rad3-related (ATR)-checkpoint kinase 1 (Chk1) pathway. Although cisplatin-based therapy is the mainstay for muscle-invasive bladder cancer (MIBC), it has a poor survival rate. Therefore, this study aimed to evaluate the efficacy of an ATR inhibitor combined with cisplatin in the treatment of APOBEC catalytic subunit 3B (APOBEC3B) expressing MIBC. Methods: Immunohistochemical staining was performed to analyze an association between APOBEC3B and ATR in patients with MIBC. The APOBEC3B expression in MIBC cell lines was assessed… More >

View

1116

Download

278

Open Access

ARTICLE

CONSTANTINE N. LOGOTHETIS¹, NATHAN P. HORVAT², TONY KURIAN³, CELESTE BELLO³, JULIO CHAVEZ³, LEIDY ISENALUMHE³, BIJAL SHAH³, LUBOMIR SOKOL³, HAYDER SAEED³, JAVIER PINILLA³, SAMEH GABALLA^3,*
Oncology Research, Vol.32, No.6, pp. 1031-1036, 2024, DOI:10.32604/or.2024.046885 - 23 May 2024
Abstract Extranodal marginal zone lymphoma (EMZL) encompasses 70% of cases of marginal zone lymphoma. Frontline bendamustine and rituximab (BR) were derived from trials involving other indolent non-Hodgkin’s lymphomas. Only one trial has evaluated frontline BR prospectively in EMZL. This retrospective study reports outcomes among EMZL patients receiving frontline BR. Twenty-five patients were included with a median age of 69 years (40–81). Five (20.0%) patients had stage I/II disease, and 20 (80.0%) had stage III/IV disease. The median number of cycles was 6.0 (3.0–6.0). Maintenance rituximab was administered to 10 (41.7%) individuals. Overall response rate (ORR) was More >

View

804

Download

261

Open Access

ARTICLE

MAHER KURDI^1,*, ALAA ALKHOTANI², ABDULRAHMAN SABBAGH³, EYAD FAIZO⁴, AHMED I. LARY⁵, AHMED K. BAMAGA⁶, MAJID ALMANSOURI⁷, BADR HAFIZ⁸, THAMER ALSHARIF⁹, SALEH BAEESA⁸
Oncology Research, Vol.32, No.6, pp. 1037-1045, 2024, DOI:10.32604/or.2024.051112 - 23 May 2024
Abstract Background: The dysregulation of Isocitrate dehydrogenase (IDH) and the subsequent production of 2-Hydroxyglutrate (2HG) may alter the expression of epigenetic proteins in Grade 4 astrocytoma. The interplay mechanism between IDH, O-6-methylguanine-DNA methyltransferase (MGMT)-promoter methylation, and protein methyltransferase proteins-5 (PRMT5) activity, with tumor progression has never been described. Methods: A retrospective cohort of 34 patients with G4 astrocytoma is classified into IDH-mutant and IDH-wildtype tumors. Both groups were tested for MGMT-promoter methylation and PRMT5 through methylation-specific and gene expression PCR analysis. Inter-cohort statistical significance was evaluated. Results: Both IDH-mutant WHO grade 4 astrocytomas (n = 22, 64.7%) and IDH-wildtype… More >

Graphic Abstract

View

1149

Download

295

Like

1

Open Access

ARTICLE

KIMBERLY FENECH¹, ISAAC MICALLEF^1,2, BYRON BARON^1,*
Oncology Research, Vol.32, No.6, pp. 1047-1061, 2024, DOI:10.32604/or.2024.049173 - 23 May 2024
Abstract Background: Colorectal cancer (CRC) is one of the most frequently diagnosed cancers. In many cases, the poor prognosis of advanced CRC is associated with resistance to treatment with chemotherapeutic drugs such as 5-Fluorouracil (5-FU). The epithelial-to-mesenchymal transition (EMT) and dysregulation in protein methylation are two mechanisms associated with chemoresistance in many cancers. This study looked into the effect of 5-FU dose escalation on EMT and protein methylation in CRC. Materials and Methods: HCT-116, Caco-2, and DLD-1 CRC cell lines were exposed to dose escalation treatment of 5-FU. The motility and invasive potentials of the cells before… More >

Graphic Abstract

View

1075

Download

264

Open Access

ARTICLE

KUN FENG^1,#, HAO PENG^2,#, QINGPENG LV¹, YEWEI ZHANG^1,*
Oncology Research, Vol.32, No.6, pp. 1063-1078, 2024, DOI:10.32604/or.2024.047078 - 23 May 2024
Abstract Hepatocellular carcinoma (HCC) is a malignancy known for its unfavorable prognosis. The dysregulation of the tumor microenvironment (TME) can affect the sensitivity to immunotherapy or chemotherapy, leading to treatment failure. The elucidation of PHLDA2’s involvement in HCC is imperative, and the clinical value of PHLDA2 is also underestimated. Here, bioinformatics analysis was performed in multiple cohorts to explore the phenotype and mechanism through which PHLDA2 may affect the progression of HCC. Then, the expression and function of PHLDA2 were examined via the qRT-PCR, Western Blot, and MTT assays. Our findings indicate a substantial upregulation of… More >

View

1094

Download

307

Open Access

ARTICLE

CHAO TANG^1,#, CHUNYU ZHONG^2,#, JUNHAO ZHU¹, FENG YUAN¹, JIN YANG¹, YONG XU^3,*, CHIYUAN MA^1,3,4,5,*
Oncology Research, Vol.32, No.6, pp. 1079-1091, 2024, DOI:10.32604/or.2024.046007 - 23 May 2024
Abstract Approximately 30%–40% of growth hormone–secreting pituitary adenomas (GHPAs) harbor somatic activating mutations in GNAS (α subunit of stimulatory G protein). Mutations in GNAS are associated with clinical features of smaller and less invasive tumors. However, the role of GNAS mutations in the invasiveness of GHPAs is unclear. GNAS mutations were detected in GHPAs using a standard polymerase chain reaction (PCR) sequencing procedure. The expression of mutation-associated maternally expressed gene 3 (MEG3) was evaluated with RT-qPCR. MEG3 was manipulated in GH3 cells using a lentiviral expression system. Cell invasion ability was measured using a Transwell assay, and epithelial–mesenchymal transition… More >

View

930

Download

294

Open Access

ARTICLE

ZHILI ZHUO^#, DONGNI ZHANG^#, WENPING LU^*, XIAOQING WU, YONGJIA CUI, WEIXUAN ZHANG, MENGFAN ZHANG
Oncology Research, Vol.32, No.6, pp. 1093-1107, 2024, DOI:10.32604/or.2024.047257 - 23 May 2024
（This article belongs to the Special Issue: New Insights in Drug Resistance of Cancer Therapy: A New Wine in an Old Bottle)
Abstract Breast cancer is the leading cause of cancer-related deaths in women worldwide, with Hormone Receptor (HR)+ being the predominant subtype. Tamoxifen (TAM) serves as the primary treatment for HR+ breast cancer. However, drug resistance often leads to recurrence, underscoring the need to develop new therapies to enhance patient quality of life and reduce recurrence rates. Artemisinin (ART) has demonstrated efficacy in inhibiting the growth of drug-resistant cells, positioning art as a viable option for counteracting endocrine resistance. This study explored the interaction between artemisinin and tamoxifen through a combined approach of bioinformatics analysis and experimental… More >

Graphic Abstract

View

1041

Download

252

Open Access

ARTICLE

ZHIGANG XIA^1,#, MENGYAO TIAN^1,#, YUCAI CHENG¹, WENFANG YI¹, ZEFAN DU^1,2, TIANWEN LI^1,2, YUCHEN WEN¹, LINDI LI^1,2, YONG LIU^1,2,*, CHUN CHEN^1,*
Oncology Research, Vol.32, No.6, pp. 1109-1118, 2024, DOI:10.32604/or.2024.049792 - 23 May 2024
Abstract Background: Chimeric antigen receptor T (CAR-T) cell therapy has achieved marked therapeutic success in ameliorating hematological malignancies. However, there is an extant void in the clinical guidelines concerning the most effective chemotherapy regimen prior to chimeric antigen receptor T (CAR-T) cell therapy, as well as the optimal timing for CAR-T cell infusion post-chemotherapy. Materials and Methods: We employed cell-derived tumor xenograft (CDX) murine models to delineate the optimal pre-conditioning chemotherapy regimen and timing for CAR-T cell treatment. Furthermore, transcriptome sequencing was implemented to identify the therapeutic targets and elucidate the underlying mechanisms governing the treatment regimen.… More >

View

1116

Download

248

Open Access

ARTICLE

YUE ZHANG^1,#, WENYU YANG^1,#, XIAOWANG HAN^1,#, YUE QIAO¹, HAITAO WANG², TING CHEN¹, TIANYING LI¹, WEN-BIN OU^1,*
Oncology Research, Vol.32, No.6, pp. 1119-1128, 2024, DOI:10.32604/or.2024.045025 - 23 May 2024
（This article belongs to the Special Issue: Signaling Pathway Crosstalk in Malignant Tumors: Molecular Targets and Combinatorial Therapeutics)
Abstract It has been shown that the high expression of human epididymis protein 4 (HE4) in most lung cancers is related to the poor prognosis of patients, but the mechanism of pathological transformation of HE4 in lung cancer is still unclear. The current study is expected to clarify the function and mechanism of HE4 in the occurrence and metastasis of lung adenocarcinoma (LUAD). Immunoblotting evaluated HE4 expression in lung cancer cell lines and biopsies, and through analysis of The Cancer Genome Atlas (TCGA) dataset. Frequent HE4 overexpression was demonstrated in LUAD, but not in lung squamous… More >

View

1279

Download

290

Open Access

ARTICLE

JUNZHE YI^1,#, BINBIN LI^2,#, XIAOMIN YIN³, LINGRUI LIU¹, CAILU SONG¹, YING ZHAO⁴, MANBO CAI³, HAILIN TANG¹, DONG CHEN^4,*, NING LYU^1,*
Oncology Research, Vol.32, No.6, pp. 1129-1139, 2024, DOI:10.32604/or.2024.047524 - 23 May 2024
Abstract Circular RNAs (circRNAs) have been recognized as pivotal regulators in tumorigenesis, yet the biological functions as well as molecular mechanisms of the majority of circRNAs in hepatocellular carcinoma (HCC) remain elusive. We sought to unveil the expression profile and biological role of circMYBL2 in HCC. Initial microarray analyses were conducted to probe the expression profile of circMYBL2 in HCC cells, and qRT‒PCR analysis was then performed in HCC cell lines and tissues, revealing significant upregulation of circMYBL2. Subsequent experiments were conducted to evaluate the biological function of circMYBL2 in HCC progression. Furthermore, bioinformatics analysis, qRT‒PCR… More >

View

1234

Download

297